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Abstract
Toxic epidermal necrolysis (TEN) is a rare, life-threatening drug-induced skin
disease with a mortality rate of approximately 30%. The clinical hallmark of TEN
is a marked skin detachment caused by extensive keratinocyte cell death
associated with mucosal involvement. The exact pathogenic mechanism of
TEN is still uncertain. Recent advances in this field have led to the identification
of several factors that might contribute to the induction of excessive apoptosis
of keratinocytes. In addition, specific human leukocyte antigen types seem to
be associated with certain drugs and the development of TEN. As
well-controlled studies are lacking, patients are treated with various
immunomodulators (e.g. intravenous immunoglobulin) in addition to the best
supportive care.
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Introduction
The exposure to drugs has increased with demographic shifts 
associated with a higher morbidity of the population. Along with 
this phenomenon, a rise in the incidence of adverse drug reactions 
(ADRs) has been observed. Toxic epidermal necrolysis (TEN) is a 
rare, acute, and life-threatening mucocutaneous disease that is usu-
ally drug related. Recent evidence situates TEN as the most severe 
form amongst a spectrum of severe epidermolytic adverse cutaneous 
drug reactions, which further include Stevens-Johnson syndrome 
(SJS) and the SJS-TEN overlap disease1. TEN is a consequence of 
extensive keratinocyte cell death that results in the separation of 
significant areas of skin at the dermal-epidermal junction with the 
production of bullae followed by skin sloughing. This extensive cell 
death also leads to mucous membrane detachment and contributes 
to the characteristic symptoms of TEN, which include high fever, 
mucositis, and moderate to severe skin pain, anxiety, and asthenia. 
Although the pathogenic mechanism of TEN remains incompletely 
understood, significant progress in this field of medicine has been 
made in recent years. The improvements range from the clinical 
classification that is essential for a better understanding of this 
disorder to the identification of genetic susceptibilities to certain 
drugs and the implementation of the first preventive genetic screen-
ing measures for selected patient groups and drug classes1. This 
review aims to provide an up-to-date overview of TEN, emphasiz-
ing pathogenesis and immunopathology.
History and epidemiology
The first description of TEN was made by the Scottish dermatolo-
gist Alan Lyell in 19562. This severe skin disease, also referred to 
as Lyell’s syndrome, was initially considered to be a toxic eruption, 
which closely resembles a severe burn or scalding of the skin2. The 
skin lesion-associated erythematous plaques and widespread areas 
of epidermal detachment were referred to by Dr. Lyell as necrolysis. 
He also described an involvement of the mucous membranes as part 
of the syndrome and noted that there was very little inflammation in 
the dermis, a feature that was later referred to as “dermal silence”3. 
TEN was only associated2 with exposure to certain medications as 
more patients presenting with TEN were reported subsequent to 
Lyell’s original publication.
TEN is a rare disease with an annual incidence of approximately 
0.4–1.2 cases per million individuals4,5. There are several factors 
that seem to impact the incidence of SJS and TEN; regional dif-
ferences in drug prescription patterns, the population’s genetic 
background such as human leukocyte antigen (HLA) status and 
phenotypes of metabolizing enzymes, co-occurrence of cancer, fre-
quency of radiotherapy, and prevalence of certain infectious diseases 
such as HIV are associated with an increased incidence of TEN6,7.
Clinical features
The main symptoms of TEN are usually preceded by non-specific 
symptoms such as fever, stinging eyes, and discomfort upon swal-
lowing by several hours up to several days. Characteristically, cuta-
neous lesions first appear in the presternal region as well as the face, 
palms, and soles of the feet. Mucosal involvement occurs in more 
than 90% of patients, predominantly affecting the mouth, genitalia, 
and/or ocular region. In some cases, the respiratory system and 
gastrointestinal tract are also affected. The morphology of lesions 
is characterized by erythema and erosions8,9. Ocular involvement 
is frequent10,11. Early cutaneous lesions frequently present as livid, 
erythematous maculae: they may or may not show signs of slight 
infiltration. During the course of the disease, the lesions rapidly 
coalesce and become tense bullae (Figure 1). With disease progres-
sions, they form large confluent areas of epidermal detachment. 
The degree of skin involvement is a highly important prognostic 
factor. Skin involvement should be determined including only 
already detached necrotic (e.g. blisters or erosions) or detachable 
skin (Nikolsky positive). A classification system for SJS and TEN 
Figure 1. Toxic epidermal necrolysis (TEN) after carbamazepine administration. (A) Skin detachment with facial erosions, including 
involvement of the lips and conjunctiva. (B) TEN with an extensive cutaneous involvement marked by detached and detachable apoptotic 
skin erosions on the trunk.
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according to the extent of skin detachment has been suggested by 
Bastuji Garin et al.12:
• 1–10%: SJS
• 11–30%: SJS-TEN overlap disease
• >30%: TEN
Furthermore, to predict the risk of death in TEN patients, the TEN-
specific severity of illness score (SCORTEN) has been proposed13.
SJS and TEN frequently leave cutaneous sequelae after healing. 
These include cutaneous hyperpigmentation and hypopigmentation 
(62.5% of cases), nail dystrophy (37.5% of cases), and ocular com-
plications (50% of cases)14,15.
In most cases of TEN, a strong, direct association of the disease with 
preceding drug consumption can be established. Indeed, preceding 
exposure to medications is reported in over 95% of patients with 
TEN, and a strong association between drug ingestion and cuta-
neous manifestation is observed in 80% of cases1. Approximately 
100 compounds have been identified as the likely triggers of 
TEN so far, the most frequent being allopurinol, antibiotics, 
nonsteroidal anti-inflammatory drugs, and anticonvulsants1,16.
Pathogenesis
So far, the precise molecular and cellular pathogenic mechanisms 
leading to the development of SJS/TEN can be only partially 
explained. It is thought to be initiated by an immune response to 
an antigenic drug-host tissue complex9,17–20. Current scientific 
opinion proposes three different hypotheses as to the formation of 
the antigenic complex (Figure 2): i) covalent binding of the drug 
to a peptide of the cellular surface (hapten/pro-hapten concept); 
ii) non-covalent, direct interaction of the drug with a specific major 
histocompatibility complex (MHC) class I allotype (p-i concept); and 
iii) presentation of an altered-self repertoire by direct drug-MHC I 
interaction (altered peptide concept). The first, the well-known hap-
ten model, is far less likely to be HLA restricted. However, the two 
remaining concepts do favor specific HLA phenotypes. According 
to the latter two hypotheses, a pharmacological agent serving as 
the allergen would directly bind to specific HLA molecules and/or 
Figure 2. Conceptual models concerning T cell stimulation by drugs in Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis 
(TEN). (A) Drugs inducing an adverse skin reaction are not antigenic by themselves. Instead, their immunogenicity may result from binding 
to carrier proteins, which allows the formation of neoantigens that are recognized by T cells upon presentation by antigen-presenting cells 
(APCs). (B) The p-i concept is based on the pharmacological interactions of drugs with immune receptors. Consistent with this concept, 
chemically inert drugs, which are unable to bind covalently to proteins, may activate specific T cells by binding directly to T cell receptors 
and/or major histocompatibility complex molecules. (C) The association of peptides with HLA molecules is highly specific. According to the 
“altered peptide model”, specific HLA molecules form a complex with certain drugs, thereby modifying the pool of self-peptides presented to 
T cells. This may result in increased autoimmunity. Concepts for immunological responses of SJS/TEN modified from Abe et al.52.
Hapten/pro-hapten
concept
p-i concept Altered peptideCBA
drug antigen (peptide)
HLA HLA HLA
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T cell receptors without prior processing by antigen-presenting 
cells. In the case of the p-i concept, the mere pharmacological 
interaction of certain drugs with immune receptors would be suf-
ficient to induce a drug hypersensitivity reaction21–24. Additionally, 
recent publications have shown that the HLA-peptide repertoire can 
be modified by abacavir and carbamazepine, resulting in enhanced 
peptide presentation and increased autoimmune reactivity (altered 
peptide model)24,25. Besides, it has been suggested that SJS may 
be induced via direct interaction between carbamazepine and 
HLA-B*150226,27. However, the identification of specific drug-related 
HLA alleles that strongly increase the likelihood of developing 
SJS or TEN strengthens the hypothesis of the genetic susceptibility 
of patients to TEN, supporting the concept of HLA-restricted drug 
presentation28–30. This finding is clinically relevant, as screening for 
the HLA-B*1502 allele in Asian patients prior to drug intake may 
identify persons at risk of developing severe epidermolytic adverse 
cutaneous drug reactions, for example in the case of carbamazepine-
induced SJS or TEN31. Evidence suggests that immune activation by 
the drug-host tissue complex induces a strong expression of Fas-L, 
a cytolytic molecule, on keratinocytes as well as granulysin 
and annexin A1 secretion by CTLs, NK cells, NKT cells, and 
monocytes32–37 (Figure 3). As a result, Fas-L- and granulysin-
mediated apoptosis and/or annexin-dependent necroptosis of 
keratinocytes with subsequent epidermal necrosis and detachment 
develop. This indicates that the disturbance of the balance between 
pro-inflammatory and immunomodulatory mechanisms may criti-
cally determine the clinical outcome in cutaneous inflammation. 
Interestingly, Th17 cells were found alongside CD8+ T cells in the 
blister fluid of SJS/TEN patients, but not in patients with erythema 
multiforme major (EMM). CD8+ T cells are a source of IL-17, 
which is a cytokine that promotes the recruitment of neutrophils38. 
Involvement of skin homing Th17 cells in SJS/TEN is suggested 
by an observed decrease in the periphery upon treatment-related 
disease improvement. Recent findings suggest that Th17 cells may 
alter their phenotype and become regulatory T cells39. Furthermore, 
recently it has been proposed that Th17 cells originally infiltrate 
skin lesions in SJS/TEN with regard to the described presence of 
granulysin-expressing drug-reactive Th17 cells40. The decrease 
Figure 3. Proposed pathogenic mechanisms in toxic epidermal necrolysis (TEN). (A) The causative medication might induce upregulation 
of Fas-L by keratinocytes constitutively expressing Fas, leading to activation of a death receptor-mediated apoptotic pathway. (B) The drug 
might interact with major histocompatibility complex class I-expressing cells, causing drug-specific CD8+ cytotoxic T cells to accumulate 
within epidermal blisters, releasing perforin and granzyme B that can kill keratinocytes. (C) Drug-activated monocytes secrete annexin 
A1, which induces necroptosis in keratinocytes. (D) The drug may also trigger the activation of CD8+ T cells, NK cells and NKT cells to 
secrete granulysin, which can induce keratinocyte death without the need for cell contact. This figure has been modified from French et al.1. 
(APC, antigen-presenting cell; NK cell, natural killer cell; NKT cell, natural killer T cell).
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in Th17 cells in patients with resolving SJS/TEN could therefore 
be associated with a simultaneous rise in regulatory T cells. This 
hypothesis should be examined in future studies. Neutropenia is 
generally associated with a higher mortality in SJS/TEN patients41.
Treatment
Rapid histological examination including direct immunofluores-
cence analysis of a lesional skin biopsy is paramount in the diag-
nostic work-up of SJS/TEN, as it helps to rule out diagnoses that 
can imitate TEN clinically. Autoimmune blistering diseases, fixed 
drug eruption (FDE), acute generalized exanthematous pustulosis 
(AGEP), and staphylococcal scalded skin syndrome (SSSS) should 
be ruled out (Table 1). The suspect drug should be discontinued 
immediately and supportive therapy should be ensured in the burn 
or intensive care unit42. However, valid data on effective therapeutic 
options are poor, and prospective controlled clinical trials, which 
can clearly show the benefit of certain treatment options, are lacking. 
Some case reports and case series report a benefit of cyclosporine, 
cyclophosphamide, N-acetylcysteine, TNF-α antagonists (e.g. 
etanercept and infliximab), systemic corticosteroids (favoring 
pulsed corticosteroid treatment), thalidomide, plasmapheresis, and 
intravenous immunoglobulin (IVIG) (reviewed in 1). Early admin-
istration of high-dose IVIGs (≤2 g/kg) is recommended for patients 
with TEN, even though its mechanism of action remains unclear43–45. 
According to a recent meta-analysis of observational studies, IVIG 
at dosages of ≤2 g/kg appears to significantly decrease mortality in 
patients with SJS or TEN43. Alternatively, cyclosporine has shown 
excellent efficacy for the treatment of TEN in a recent study46. 
However, as the supporting data for each treatment modality with 
regard to decreased mortality in TEN are highly controversial, fur-
ther evidence based on multicenter, randomized, controlled clinical 
trials is still to be defined.
Allergologic work-up
The allergologic work-up to identify the causative agents includes 
skin tests (epicutaneous testing47), in vitro assays (lymphocyte 
transformation tests [LTTs]48–50), and drug-induced cytokine pro-
duction assays (e.g. enzyme-linked immunospot [ELISpot]51). Skin 
tests have been shown to be safe in TEN patients, but their spe-
cificity and sensitivity are rather low51. In a recent report, Barbaud 
et al. performed skin patch testing to identify the causative agent in 
17 patients who had suffered from SJS and/or TEN. Positive patch 
test reactions were observed in only 24% of those patients52. Con-
cerning in vitro tests, it should be noted that the LTT is not a stand-
ardized procedure and merely demonstrates the proliferation of 
lymphocytes in the presence of various compounds. However, LTT 
in patients with SJS/TEN has shown low sensitivity, even if per-
formed by highly qualified personnel53.
Table 1. Diagnostic algorithm for patients with suspected severe adverse cutaneous drug reactions. AGEP, acute 
generalized exanthematous pustulosis; DRESS, drug reaction with eosinophilia and systemic reaction; MPR, maculopapular 
rash; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis.
Suspicion of severe adverse drug reaction
Facial edema
Blood eosinophilia
Mucous or conjunctival lesions
Painful eyes or skin
Epidermal detachment/erosions
MPR DRESS AGEP SJS/TEN
Maculopapular 
exanthema
No skin detachment
No organ involvement
Facial edema
Maculopapular exanthema
Fever
Blood eosinophilia
Leukocytosis with atypical 
lymphocytes
Organ involvement (lymph 
nodes, liver, and kidneys)
Acute sterile pustular eruption
Erythema of the skin
Fever
Blood neutrophilia
Facial edema
Painful maculopapular exanthema
Possibly atypical targetoid lesions
Skin detachment
Mucosal and conjunctival erosions
SJS SJS/TEN TEN
Detached/
detachable 
skin <10%
Detached/
detachable 
skin 
10%–30%
Detached/
detachable 
skin >30%
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Conclusion
Since the time TEN was first described by Dr. Lyell, it has remained 
a deadly disease with a mortality of around 30%. There is an unmet 
need to study the pathophysiology of TEN in more detail, which is 
complicated by the rarity of this disease and the lack of appropriate 
mouse models. Additionally, effective therapeutic options validated 
by prospective, randomized, controlled trials remain to be discov-
ered. The most important therapeutic measure so far remains the 
rapid identification and withdrawal of the causative drug in addi-
tion to supportive care. However, this can be a complicated task in 
patients with polymedication. The allergologic work-up is further 
complicated by the lack of safe test methods with a high sensitivity 
and specificity.
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